Administration of Hoisted Cholesterol in the Essential Counteractive action Gathering of Grown-up Japanese (Uber) Trial.


74 views
Uploaded on:
Description
Super Trial: Background. In Japan, the rate of coronary infection is around 33% lower than the US and Europe, where the greater part of the statin trials have been led The objective of this study was to look at whether the expansion of a low-measurements statin to an eating regimen rich in omega-3 unsaturated fats could decrease the danger of CHD..
Transcripts
Slide 1

Super Trial Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial Presented at The American Heart Association Scientific Session 2005 Presented by Dr. Haruo Nakamura

Slide 2

MEGA Trial: Background In Japan, the frequency of coronary malady is around 33% lower than the US and Europe, where the majority of the statin trials have been led The objective of this study was to analyze whether the expansion of a low-measurements statin to an eating regimen rich in omega-3 unsaturated fats could decrease the danger of CHD. Introduced at AHA 2005

Slide 3

MEGA Trial 7,832 men age 40-70 years and postmenopausal ladies up to age 70 with aggregate cholesterol 220-270 mg/dL Mean BMI 23.8 kg/m2, 21% Diabetics, 20% Current Smokers, pattern all out cholesterol 242.6 mg/dL, LDL 157 mg/dL, HDL 57.5 mg/dL, triglycerides 127 mg/dL 32% Female, Mean Age 58 years, Mean Follow-Up 5.3 years Prospective. Randomized. Open-mark. Diet Modification n=3,966 Diet Modification + Pravastatin 10-20 mg/day n=3,866 Primary Endpoints: Composite of coronary illness occasions, characterized as heart and sudden demise, deadly and nonfatal myocardial localized necrosis (MI), angina and cardiovascular or vascular intercession. Optional Endpoints: Stroke, CHD composite or cerebral dead tissue, any cardiovascular occasion, all out mortality. Exhibited at AHA 2005

Slide 4

MEGA Trial: Cholesterol and Triglyceride Levels Total Cholesterol HDL Triglycerides LDL Total cholesterol diminishment was bigger in the pravastatin bunch LDL lessening was more prominent in the pravastatin bunch HDL increment was more noteworthy in the pravastatin bunch Triglyceride decrease was more prominent in the pravastatin bunch mg/dL Presented at AHA 2005

Slide 5

MEGA Trial: Primary Composite Endpoint Primary composite endpoint of coronary illness occasions p = 0.01 The essential composite endpoint of coronary illness occasions happened less habitually in the pravastatin in addition to eating routine gathering (3.3 versus 5.0 for each 1000 patient years, risk proportion [HR] 0.67, p=0.01). # per 1000 patient years Presented at AHA 2005

Slide 6

MEGA Trial: Secondary Endpoints Total mortality was non-fundamentally bring down in the pravastatin bunch (2.7 versus 3.8, HR 0.71, p=0.055) MI happened less regularly in the pravastatin bunch (0.9 versus 1.6, p=0.03) No huge contrast was seen in stroke (2.5 versus 3.0, p=0.33) or cerebral localized necrosis in addition to TIA (2.0 versus 2.6, p=0.23) p=0.055 p=0.33 p=0.23 p=0.03 # per 1000 patient years Presented at AHA 2005

Slide 7

MEGA Trial: Secondary Endpoints cont. Composite of CHD occasion or cerebral localized necrosis p = 0.005 The composite of CHD occasion or cerebral dead tissue was lower in the pravastatin bunch (5.0 versus 7.1, p=0.005) # per 1000 patient years Presented at AHA 2005

Slide 8

MEGA Trial: Safety Data Frequency of tumor (per 1000 patient years) Frequency of raised liver capacity variations from the norm (%) % # per 1000 patient years There was no distinction in the recurrence of growth or lifted liver capacity anomalies and no instances of rhabdomyolysis. Introduced at AHA 2005

Slide 9

MEGA Trial: Summary Among Japanese patients with hypercholesterolemia, treatment with pravastatin treatment notwithstanding diet alteration was connected with a diminishment in the essential composite endpoint of coronary illness occasions contrasted and eat less adjustment alone at a mean 5.3 year development. Past studies directed in western populaces have indicated diminishments in antagonistic coronary occasions connected with statin treatment use; in any case, the heart horribleness and mortality in Japan is much lower than in the U.S. what\'s more, other western nations where statin treatment has been transcendently considered. The present study exhibited that even in this lower hazard populace, essential counteractive action with low-measurement statin treatment can be viable in diminishing cardiovascular occasions, with an unobtrusive decrease in lipid parameters. Introduced at AHA 2005

Recommended
View more...